IRAK4-IN-7 CA-4948 CAS: 1801343-74-7

IRAK4-IN-7, also known as CA-4948, is a chemical compound that has been developed for its potential therapeutic applications. It belongs to the class of IRAK4 inhibitors, which are used in the treatment of autoimmune diseases and cancer. In this article, we will provide an overview of IRAK4-IN-7, including its chemical name, molecular formula, formula weight, CAS No., top ten keywords, synonyms, health benefits, potential effects, product mechanism, safety, side effects, and dosing information.

Chemical Name: The chemical name of IRAK4-IN-7 is 2-cyclopropyl-5-(6-methylpyridin-2-yl)-1,3,4-thiadiazole.

Molecular Formula: The molecular formula of IRAK4-IN-7 is C11H11N3S.

Formula Weight: The formula weight of IRAK4-IN-7 is 225.29 g/mol.

CAS No: The CAS number of IRAK4-IN-7 is 1801343-74-7.

Top Ten Keywords: The top ten keywords associated with IRAK4-IN-7 CAS: 1801343-74-7 are:

1. IRAK4-IN-7
2. IRAK4 inhibitor
3. Autoimmune diseases
4. Cancer
5. Small molecule inhibitor
6. Anti-inflammatory
7. Toll-like receptor signaling
8. Therapeutic applications
9. Immune system
10. Chemotherapy

Synonyms: The synonyms for IRAK4-IN-7 include:

1. CA-4948
2. 2-Cyclopropyl-5-(6-methylpyridin-2-yl)-1,3,4-thiadiazole
3. IRAK inhibitor
4. Small molecule IRAK4 inhibitor

Health Benefits: IRAK4-IN-7 has potential health benefits due to its ability to inhibit the activity of IRAK4, which plays a crucial role in the activation of the immune system and the development of inflammation. It has been studied for its potential use in the treatment of autoimmune diseases and cancer.

Potential Effects: The potential effects of IRAK4-IN-7 include:

1. Reduction of inflammation: IRAK4-IN-7 can reduce inflammation by inhibiting the activity of IRAK4, which plays a key role in the activation of the immune system and the production of inflammatory cytokines.
2. Treatment of autoimmune diseases: IRAK4-IN-7 may be able to treat autoimmune diseases by reducing the activity of the immune system, which can attack healthy tissues and cause damage.
3. Treatment of cancer: IRAK4-IN-7 has been shown to have potential anticancer effects by inhibiting the activity of IRAK4, which is involved in the survival and proliferation of cancer cells.

Product Mechanism: IRAK4-IN-7 works by inhibiting the activity of IRAK4, which is a key enzyme involved in the Toll-like receptor signaling pathway. This pathway plays a crucial role in the activation of the immune system and the production of inflammatory cytokines. By inhibiting the activity of IRAK4, IRAK4-IN-7 can reduce inflammation and potentially treat autoimmune diseases and cancer.

Safety: The safety of IRAK4-IN-7 has not been extensively studied, but it is thought to be generally safe when used as directed. However, like any new drug, there may be some potential risks associated with its use.

Side Effects: The side effects of IRAK4-IN-7 are not well known, but some possible side effects may include nausea, vomiting, diarrhea, and fatigue.

Dosing Information: The optimal dose of IRAK4-IN-7 has not been established yet, and further studies are needed to determine the appropriate dosage for different conditions.

Conclusion: IRAK4-IN-7 represents a promising new compound with potential therapeutic applications in the fields of autoimmune diseases and cancer. It works by inhibiting the activity of IRAK4, which plays a crucial role in the activation of the immune system and the production of inflammatory cytokines. While the safety and side effects of IRAK4-IN-7 are not well understood, further research is needed to establish its optimal dosage and ensure its safety in clinical trials. Overall, IRAK4-IN-7 presents an exciting avenue for the development of innovative therapies for a variety of diseases, including autoimmune disorders and cancer